You are currently logged into
POZ Directory - My Account or Log Out
POZ POZ
  • Home
  • Basics
    • Basics
    • Introduction
    • HIV Transmission and Risks
    • HIV Testing
    • HIV Prevention
    • Newly Diagnosed
    • Starting HIV Treatment
    • HIV Medications
    • HIV Drug Assistance Programs
    • HIV and Liver Disease
    • VIH/SIDA en Español
  • News
    • News
    • Newsfeed
    • Treatment News
    • Features
    • Opinions
    • Conferences
    • Slideshows
    • Videos
    • POZ at Home
    • POZ TV
    • POZ Stories
    • POZ 100
    • By Author
    • RSS Links
  • Hot Topics
    • Hot Topics
    • POZ Awards
    • POZ at 25
    • POZ 100
    • Advocacy
    • COVID-19
    • Criminalization
    • Cure
    • Long-Term Survivors
    • Newly Diagnosed
    • PrEP
    • Prevention
    • Undetectable (U=U)
    • Youth
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • POZ Focus
    • POZ en Español
    • Subscriptions
    • Email Newsletters
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Community
    • POZ Personals
    • POZ Stories
    • POZ 100
    • Community
    • AIDS Is Everyday
    • Forums
    • Polls
    • Surveys
    • Quizzes
    • Ask POZ
    • Services Directory
    • Calendar
    • Jobs
    • Bookstore
  • About Us
    • About Us
    • About Us
    • Masthead
    • Awards
    • Press Releases
    • Advertise
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#Cimduo

Tweet
  • Share

Temixys

Temixys

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

Only Subnormal Kidney Function May Get Boost From Switch to New Tenofovir

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

HIV Medication Epivir Could Possibly Treat Alzheimer’s

Research in human cells and mice found the antiretroviral suppressed harmful chronic inflammation linked to age-related disorders.

Gilead’s float in the Seattle LGBT pride parade, June 2017

Is Gilead’s Entire HIV Enterprise Built on a False Promise?

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

FDA OKs Symfi, Mylan’s Third Cut-Price Single-Tablet HIV Regimen

The tablet contains the same combo as Symfi Lo (efavirenz/lamivudine/tenofovir disoproxil fumarate) but with a higher dose of efavirenz.

FDA Approves Mylan’s Cut-Price HIV Tablets Symfi Lo and Cimduo

Symfi Lo contains efavirenz, lamivudine and tenofovir disoproxil fumarate (TDF); Cimduo contains TDF and lamivudine.

Cimduo

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.